A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol,2 in treating mild to moderate persistent asthma in children ages 6 to 15 years old2 who were previously treated with an inhaled corticosteroid (ICS).2 Of note.

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease.

Two studies that offer new insights to help adolescents and younger children improve their asthma control will be presented by researchers from Cincinnati Children’s Hospital Medical Center at this year’s annual meeting of the Pediatric Academic Society (PAS) in Honolulu, Hawaii.

A new study reports that inner-city children with asthma may be particularly vulnerable to air pollution at levels below current air quality standards. The study, available online today, analyzes the short-term effects of outdoor pollution levels on asthma symptoms and lung function in children. The study was supported by the National Institutes of Health (NIH) and the Environmental Protection Agency (EPA).

When an asthma attack occurs, many sufferers use a device — a “spacer” — to increase the chances that rescue medicine travels from an inhaler all the way down to the airways where it is needed. A new review of studies found no difference between the effectiveness of commercially manufactured devices and homemade spacers — sometimes fashioned from a plastic soda bottle or a Styrofoam cup.

A study has found only 16% of the 352,082 Australians who filled a prescription for asthma preventer medications for the first time during the period July 2004 to June 2005, went on to use them regularly.

More than a decade after national guidelines were issued for asthma treatment, some patients still don’t receive prescriptions for the inhalers that experts say offer the safest and most effective long-term control of the disease, a new study suggests.

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day–to-day lung function.

Results from a new national survey demonstrate that elevated allergen levels in the home are associated with asthma symptoms in allergic individuals. The study suggests that asthmatics that have allergies may alleviate symptoms by reducing allergen exposures inside their homes.

Asthmatx, Inc., a medical device company that has developed a catheter-based procedure under investigation for the treatment of asthma, announced today the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191).

The Food and Drug Administration has approved new inhaled steroid treatment for preventing asthma attacks in young children produced by Schering-Plough Corp.

An enzyme released by mast cells in the lungs appears to play a key role in the tightening of airways that is a hallmark of asthma — pointing to a potential new target for treatment against the illness.